Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ardelyx, Inc. ARDX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$17.00
+168.6%

Ardelyx, Inc. (ARDX) is a Biotechnology company in the Healthcare sector, currently trading at $6.33. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ARDX = $17 (+168.6% upside).

Valuation: ARDX trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25).

Financials: revenue is $407M, +109.6%/yr average growth. Net income is $62M (loss), growing at -5%/yr. Net profit margin is -15.1% (negative). Gross margin is 90.3% (-1.8 pp trend).

Balance sheet: total debt is $212M against $167M equity (Debt-to-Equity (D/E) ratio 1.27, moderate). Current ratio is 4.31 (strong liquidity). Debt-to-assets is 42.2%. Total assets: $502M.

Analyst outlook: 16 / 16 analysts rate ARDX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 66/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$17.00
▲ 168.56% Upside
Average Price Target
Based on 16 Wall Street analysts offering 12-month price targets for Ardelyx, Inc., the average price target is $17.00, with a high forecast of $19.00, and a low forecast of $15.00.
Highest Price Target
$19.00
Average Price Target
$17.00
Lowest Price Target
$15.00

ARDX SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 78/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 66/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARDX

✓
VALUE Pass
78/100
ARDX trades at a trailing Price-to-Earnings (P/E) of -23.7 (S&P 500 average ~25). Trailing PEG 1.81. Analyst consensus target is $17, implying +168.6% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ARDX: +109.6%/yr revenue is, -5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ARDX: Debt-to-Equity (D/E) ratio 1.27 (moderate), Current ratio is 4.31 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
66/100
ARDX: Gross margin is 90.3% (-1.8 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 66/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 16 / 16 analysts rate ARDX as buy (100%). Analyst consensus target is $17 (+168.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ARDX: Net profit margin is -15.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.21-8.4
Volume3.7M
Avg Volume (30D)3.96M
Market Cap$1.55B
Beta (1Y)0.62
Share Statistics
EPS (TTM)-0.26
Shares Outstanding$241.03M
IPO Date2014-06-19
Employees395
CEOMichael G. Raab
Financial Highlights & Ratios
Revenue (TTM)$407.32M
Gross Profit$367.78M
EBITDA$-29.17M
Net Income$-61.6M
Operating Income$-40.98M
Total Cash$264.69M
Total Debt$211.6M
Net Debt$143.6M
Total Assets$501.6M
Price / Earnings (P/E)-24.3
Price / Sales (P/S)3.81
Analyst Forecast
1Y Price Target$17.00
Target High$19.00
Target Low$15.00
Upside+168.6%
Rating ConsensusBuy
Analysts Covering16
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS0396971071

Price Chart

Track all markets on TradingView
ARDX
Ardelyx, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
3.21 52WK RANGE 8.40

People Also View

IBRX
IBRX
ImmunityBio, Inc.
$7.60
+4.11%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 LXRX
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75
+2.34%
 VSTM
VSTM
Verastem, Inc.
$6.14
+8.48%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 MCRB
MCRB
Seres Therapeutics, Inc.
$8.61
+0.35%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message